[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019-2023 Latin America Cancer Diagnostics Market: A 7-Country Analysis--Supplier Strategies, Emerging Tumor Markers, Volume and Sales Forecasts, Technology and Instrumentation Review

January 2019 | 550 pages | ID: L97E9943AC5EN
Venture Planning Group

US$ 7,850.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new 7-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Argentina, Brazil, Chile, Colombia, Mexico, Peru, VenezuelaBusiness Opportunities and Strategic Recommendations
  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.

Over 200 current and emerging Cancer Diagnostic Tests
  • Oncogenes- Biochemical Markers- Growth Factors- Colony Stimulating Factors- Hormones- Immunohistochemical Stains- Lymphokines
  • ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Instrumentation Review
  • Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
  • Assessment of latest technologies and their potential applications for cancer diagnostic testing.
  • Review of competing/complementing technologies.
  • Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:
  • Abbott
  • AdnaGen/Alere
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics/Theradiag
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode Genetics
  • Diadexus
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enterix/Clinical Genomics
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech/Leica
  • Kyowa Medex
  • Mackay Life Sciences
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Thermo Fisher/Affymetrix
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila/Alere
Contains 550 pages and 42 tables
I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Breast Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26.. Biochemical Tumor Markers
  27. Oncogenes
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  28. Polypeptide Growth Factors
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
    Alpha-Interferon
    B Cell Growth Factors
    B Cell Growth Factor (BCGF)
    Gamma-Interferon
    Interleukin-1 (IL-1)
    Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
    N-Acetylglucosamine
    Actin
    Alpha-Actin
    Antineuronal Antibodies
    7B2
    B72.3
    Bax
    BCD-F9
    BLCA-4
    Blood Group Antigens A,B,H
    CA 50
    CA 72-4/TAG-72
    CA 195
    CA-242
    CA-549
    CAM 26
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA 93
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma 552
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor 1
    Myosin
    NEA-130
    NMP22
    OA-519
    Opioid Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL 175
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG 12
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
  3. Molecular Diagnostics
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
E. Personal Testing

VIII. COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES

Argentina
Brazil
Chile
Colombia
Mexico
Peru
Venezuela

IX. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

LIST OF TABLES

Argentina Cancer Diagnostic Volume Forecasts by Test
Argentina Cancer Diagnostics Sales Forecasts by Test
Brazil Cancer Diagnostic Volume Forecasts by Test
Brazil Cancer Diagnostics Sales Forecasts by Test
Chile Cancer Diagnostic Volume Forecasts by Test
Chile Cancer Diagnostics Sales Forecasts by Test
Colombia Cancer Diagnostic Volume Forecasts by Test
Colombia Cancer Diagnostics Sales Forecasts by Test
Mexico Cancer Diagnostic Volume Forecasts by Test
Mexico Cancer Diagnostics Sales Forecasts by Test
Peru Cancer Diagnostic Volume Forecasts by Test
Peru Cancer Diagnostics Sales Forecasts by Test
Venezuela Cancer Diagnostic Volume Forecasts by Test
Venezuela Cancer Diagnostics Sales Forecasts by Test
Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis


More Publications